Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD4205 |
Synonyms | |
Therapy Description |
AZD4205 is a selective inhibitor of JAK1, which reduces downstream signaling and may lead to inhibition of cell proliferation and tumor growth (PMID: 32297743, NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD4205 | AZD 4205|AZD-4205|Golidocitinib | JAK1 Inhibitor 9 | AZD4205 is a selective inhibitor of JAK1, which reduces downstream signaling and may lead to inhibition of cell proliferation and tumor growth (PMID: 32297743, NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04105010 | Phase II | AZD4205 | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Recruiting | USA | 3 |